Literature DB >> 10944440

Effect of advanced glycation end products on lens epithelial cells in vitro.

S B Hong1, K W Lee, J T Handa, C K Joo.   

Abstract

The extended exposure of proteins to reducing sugars leads to nonenzymatic glycation with the accumulation of advanced glycation end products (AGEs). Long-lived proteins, such as collagen and crystallins, are subjected to this modification, and are implicated as causal factors in several diseases including diabetic complications, cataracts, and arteriosclerosis. One means through which AGEs modulate cellular interactions is via binding to specific receptors. In the current study, the existence of AGEs in human anterior polar lens capsules of cataracts was confirmed using a combination of dot-immunoblot and fluorescent detection. Human lens epithelial cells (LECs) attached to anterior lens capsules expressed mRNA for the receptor for AGEs (RAGE). The interaction of LECs with AGEs using bovine lens epithelial explants demonstrated that AGEs induced mRNAs and proteins of fibronectin, collagen type I, aberrant extracellular matrix proteins, and alpha-SMA, a specific marker for myofibroblastic cells. These findings suggest that AGEs may alter cellular functions which induce mRNAs and proteins associated with fibrosis in LECs. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10944440     DOI: 10.1006/bbrc.2000.3245

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Risk factors for incident cortical, nuclear, posterior subcapsular, and mixed lens opacities: the Los Angeles Latino eye study.

Authors:  Grace M Richter; Farzana Choudhury; Mina Torres; Stanley P Azen; Rohit Varma
Journal:  Ophthalmology       Date:  2012-07-06       Impact factor: 12.079

2.  Evaluation of advanced glycation end-products in diabetic and inherited canine cataracts.

Authors:  I Dineli Bras; Carmen M H Colitz; Donna F Kusewitt; Heather Chandler; Ping Lu; Anne J Gemensky-Metzler; David A Wilkie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02       Impact factor: 3.117

3.  GLO1 gene polymorphisms and their association with retinitis pigmentosa: a case-control study in a Sicilian population.

Authors:  Luigi Donato; Concetta Scimone; Giacomo Nicocia; Lucia Denaro; Renato Robledo; Antonina Sidoti; Rosalia D'Angelo
Journal:  Mol Biol Rep       Date:  2018-08-11       Impact factor: 2.316

4.  KIOM-79 Prevents Lens Epithelial Cell Apoptosis and Lens Opacification in Zucker Diabetic Fatty Rats.

Authors:  Junghyun Kim; Chan-Sik Kim; Eunjin Sohn; Hyojun Kim; Il-Ha Jeong; Jin Sook Kim
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-07       Impact factor: 2.629

5.  Diabetic cataract-pathogenesis, epidemiology and treatment.

Authors:  Andreas Pollreisz; Ursula Schmidt-Erfurth
Journal:  J Ophthalmol       Date:  2010-06-17       Impact factor: 1.909

Review 6.  The lens capsule.

Authors:  Brian P Danysh; Melinda K Duncan
Journal:  Exp Eye Res       Date:  2008-08-16       Impact factor: 3.467

7.  Lens epithelial cell apoptosis initiates diabetic cataractogenesis in the Zucker diabetic fatty rat.

Authors:  Junghyun Kim; Chan-Sik Kim; Eunjin Sohn; Hyojun Kim; Il-Ha Jeong; Jin Sook Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

8.  Accumulation of argpyrimidine, a methylglyoxal-derived advanced glycation end product, increases apoptosis of lens epithelial cells both in vitro and in vivo.

Authors:  Junghyun Kim; Ohn Soon Kim; Chan-Sik Kim; Eunjin Sohn; Kyuhyung Jo; Jin Sook Kim
Journal:  Exp Mol Med       Date:  2012-02-29       Impact factor: 8.718

9.  Investigation of synergistic mechanism and identification of interaction site of aldose reductase with the combination of gigantol and syringic acid for prevention of diabetic cataract.

Authors:  Jie Wu; Xue Li; Hua Fang; Yanqun Yi; Dan Chen; Yan Long; Xinxin Gao; Xiaoyong Wei; C-Y Oliver Chen
Journal:  BMC Complement Altern Med       Date:  2016-08-12       Impact factor: 3.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.